Page last updated: 2024-10-21

xanthine and Asthma

xanthine has been researched along with Asthma in 9 studies

7H-xanthine : An oxopurine in which the purine ring is substituted by oxo groups at positions 2 and 6 and N-7 is protonated.
9H-xanthine : An oxopurine in which the purine ring is substituted by oxo groups at positions 2 and 6 and N-9 is protonated.

Asthma: A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).

Research Excerpts

ExcerptRelevanceReference
"The effect of aminophylline administered intravenously in dose 250 mg on plasma oxypurines (hypoxanthine and xanthine) concentration as well as on plasma adenosine deaminase activity and plasma AMP deaminase activity was studied in 17 patients with bronchial asthma or chronic cor pulmonale."7.68[The effect of aminophylline on plasma oxypurines in patients with bronchial asthma or cor pulmonale]. ( Banaszak, F; Głuszek, J; Tykarski, A, 1991)
"The effect of increasing intravenous doses of theophylline and enprofylline, a new xanthine derivative, on bronchial responsiveness to methacholine was studied in eight asthmatic patients."5.06Effect of theophylline and enprofylline on bronchial hyperresponsiveness. ( Boorsma, M; Jonkman, JH; Koëter, GH; Kraan, J; van der Mark, TW, 1989)
"The effect of aminophylline administered intravenously in dose 250 mg on plasma oxypurines (hypoxanthine and xanthine) concentration as well as on plasma adenosine deaminase activity and plasma AMP deaminase activity was studied in 17 patients with bronchial asthma or chronic cor pulmonale."3.68[The effect of aminophylline on plasma oxypurines in patients with bronchial asthma or cor pulmonale]. ( Banaszak, F; Głuszek, J; Tykarski, A, 1991)
"Xanthine was still the most frequently used medication for asthmatic patients (60."1.42Analysis of prescription pattern and guideline adherence in the management of asthma among medical institutions and physician specialties in Taiwan between 2000 and 2010. ( Chen, TJ; Chou, CL; Chou, YC; Lin, AM; Lin, TL; Perng, DW; Wu, MS, 2015)

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19903 (33.33)18.7374
1990's2 (22.22)18.2507
2000's1 (11.11)29.6817
2010's3 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Basu, S1
Barawkar, DA1
Ramdas, V1
Patel, M1
Waman, Y1
Panmand, A1
Kumar, S1
Thorat, S1
Naykodi, M1
Goswami, A1
Reddy, BS1
Prasad, V1
Chaturvedi, S1
Quraishi, A1
Menon, S1
Paliwal, S1
Kulkarni, A1
Karande, V1
Ghosh, I1
Mustafa, S1
De, S1
Jain, V1
Banerjee, ER1
Rouduri, SR1
Palle, VP1
Chugh, A1
Mookhtiar, KA1
Albers, FC1
Price, RG1
Smith, SG1
Yancey, SW1
Chou, CL1
Perng, DW1
Lin, TL1
Lin, AM1
Chen, TJ1
Wu, MS1
Chou, YC1
CASS, LJ1
FREDERIK, WS1
NELSON, LS1
STOESSER, AV1
Daly, JW1
Banaszak, F1
Głuszek, J1
Tykarski, A1
Anderson, HR1
Koëter, GH1
Kraan, J1
Boorsma, M1
Jonkman, JH1
van der Mark, TW1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
MEA115588 A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma[NCT01691521]Phase 3580 participants (Actual)Interventional2012-10-08Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Mean Change From Baseline in Clinic Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 32

FEV1 is defined as the volume of air expelled from the lungs in 1 second. Pre-bronchodilator FEV1 measurements were taken by spirometry. The change from Baseline is defined as the difference between the value of the endpoint at the time point of interest and the baseline value. Analysis performed using mixed model repeated measures with covariates of baseline, region, baseline maintenance OCS therapy (OCS vs. no OCS), exacerbations in the year prior to the study (as an ordinal variable), treatment and visit, plus interaction terms for visit by baseline and visit by treatment group. (NCT01691521)
Timeframe: Baseline, Week 32

InterventionMilliliters (mL) (Least Squares Mean)
Placebo86
Mepolizumab 75 mg IV186
Mepolizumab 100 mg SC183

Mean Change From Baseline in the St. George's Respiratory Questionnaire Total Score at Week 32

The St. George's Respiratory Questionnaire is an established instrument, comprising 50 questions, evaluating symptoms, activity, and impacts; to measure Quality of Life in participants with diseases of airway obstruction and to elicit the participant's opinion of his/her health. The lowest possible value is zero and the highest possible value is 100. The higher values correspond to greater impairment in quality of life. The questionnaire was administered at Baseline (Visit 2) and at the Exit Visit (approximately 4 weeks after the last dose of study treatment). The change from baseline is defined as the difference between the value of the endpoint at the time point of interest and the baseline value. Analysis performed using analysis of covariance with covariates of baseline, region, baseline maintenance OCS therapy (OCS vs. no OCS), exacerbations in the year prior to the study (as an ordinal variable), baseline % predicted FEV1, and treatment. (NCT01691521)
Timeframe: Baseline, Week 32

InterventionScores on a scale (Least Squares Mean)
Placebo-9.0
Mepolizumab 75 mg IV-15.4
Mepolizumab 100 mg SC-16.0

Number of Clinically Significant Exacerbations of Asthma Per Year

Clinically significant exacerbations of asthma are defined as worsening of asthma which required use of systemic corticosteroids (IV or oral steroid like prednisone, for at least 3 days or a single intramuscular (IM) corticosteroid (CS) dose is required. For maintenance of systemic corticosteroids, at least double the existing maintenance dose for at least 3 days was required) and/or hospitalization and/or emergency department (ED) visits. The frequency of clinically significant exacerbations of asthma over the 32-week treatment period is expressed as the number of exacerbations per year. Analysis of the number of exacerbations performed using a negative binomial model with covariates of treatment group, baseline maintenance OCS therapy (OCS vs. no OCS), region, exacerbations in the year prior to the study (as an ordinal variable) and baseline % predicted FEV1, and with logarithm of time on treatment as an offset variable. (NCT01691521)
Timeframe: From randomization (Week 0) to Week 32 or if Early Withdrawal (EW) 4 weeks post last dose

InterventionNumber of exacerbations per year (Number)
Placebo1.74
Mepolizumab 75 mg IV0.93
Mepolizumab 100 mg SC0.83

Number of Clinically Significant Exacerbations Requiring Hospitalization (Including Intubation and Admittance to an ICU) Per Year

Clinically significant exacerbations of asthma is defined as worsening of asthma which required use of systemic corticosteroids (IV or oral steroid like prednisone, for at least 3 days or a single intramuscular (IM) corticosteroid (CS) dose is required. For maintenance of systemic corticosteroids, at least double the existing maintenance dose for at least 3 days was required) and/or hospitalization. The frequency of clinically significant exacerbations of asthma over the 32-week treatment period is expressed as the number of exacerbations per year. Analysis of the number of exacerbations performed using a negative binomial model with covariates of treatment group, baseline maintenance OCS therapy (OCS vs. no OCS), region, exacerbations in the year prior to the study (as an ordinal variable) and baseline % predicted FEV1, and with logarithm of time on treatment as an offset variable. (NCT01691521)
Timeframe: From randomization (Week 0) to Week 32 or if Early Withdrawal (EW) 4 weeks post last dose

InterventionNumber of exacerbations per year (Number)
Placebo0.10
Mepolizumab 75 mg IV0.06
Mepolizumab 100 mg SC0.03

Number of Clinically Significant Exacerbations Requiring Hospitalization (Including Intubation and Admittance to an Intensive Care Unit [ICU]) or ED Visits Per Year

Clinically significant exacerbations of asthma are defined as worsening of asthma which required use of systemic corticosteroids (IV or oral steroid like prednisone, for at least 3 days or a single intramuscular (IM) corticosteroid (CS) dose is required. For maintenance of systemic corticosteroids, at least double the existing maintenance dose for at least 3 days was required) and/or hospitalization and/or emergency department (ED) visits. The frequency of clinically significant exacerbations of asthma over the 32-week treatment period is expressed as the number of exacerbations per year. Analysis of the number of exacerbations performed using a negative binomial model with covariates of treatment group, baseline maintenance OCS therapy (OCS vs. no OCS), region, exacerbations in the year prior to the study (as an ordinal variable) and baseline % predicted FEV1, and with logarithm of time on treatment as an offset variable. (NCT01691521)
Timeframe: From randomization (Week 0) to Week 32 or if Early Withdrawal (EW) 4 weeks post last dose

InterventionNumber of exacerbations per year (Number)
Placebo0.20
Mepolizumab 75 mg IV0.14
Mepolizumab 100 mg SC0.08

Reviews

1 review available for xanthine and Asthma

ArticleYear
Caffeine analogs: biomedical impact.
    Cellular and molecular life sciences : CMLS, 2007, Volume: 64, Issue:16

    Topics: Alzheimer Disease; Asthma; Biomedical Research; Caffeine; Calcium; Central Nervous System Stimulants

2007

Trials

2 trials available for xanthine and Asthma

ArticleYear
Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies.
    The Journal of allergy and clinical immunology, 2017, Volume: 140, Issue:5

    Topics: Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Anti-Asthmatic Agents; Antibodies, Mon

2017
Effect of theophylline and enprofylline on bronchial hyperresponsiveness.
    Thorax, 1989, Volume: 44, Issue:12

    Topics: Adult; Airway Resistance; Asthma; Bronchi; Bronchial Provocation Tests; Bronchodilator Agents; Doubl

1989

Other Studies

6 other studies available for xanthine and Asthma

ArticleYear
Design and synthesis of novel xanthine derivatives as potent and selective A
    European journal of medicinal chemistry, 2017, Jul-07, Volume: 134

    Topics: Adenosine A2 Receptor Antagonists; Animals; Asthma; Dogs; Drug Design; Hep G2 Cells; Humans; Madin D

2017
Analysis of prescription pattern and guideline adherence in the management of asthma among medical institutions and physician specialties in Taiwan between 2000 and 2010.
    Clinical therapeutics, 2015, Oct-01, Volume: 37, Issue:10

    Topics: Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Adult; Ambulatory Care; Anti-Asthmatic

2015
A new xanthine derivative: theophylline with diethylenediamine; a clinical study.
    New York state journal of medicine, 1958, Jul-15, Volume: 58, Issue:14

    Topics: Asthma; Biomedical Research; Piperazines; Theophylline; Xanthine; Xanthines

1958
CLINICAL ADVANTAGES OF ISOEPHEDRINE OVER EPHEDRINE WITH XANTHINE DERIVATIVES AND EXPECTORANTS IN MILD AND MODERATELY SEVERE ASTHMA.
    Annals of allergy, 1964, Volume: 22

    Topics: Adolescent; Asthma; Diuretics; Drug Therapy; Ephedrine; Expectorants; Geriatrics; Glycerol; Guaiacol

1964
[The effect of aminophylline on plasma oxypurines in patients with bronchial asthma or cor pulmonale].
    Polskie Archiwum Medycyny Wewnetrznej, 1991, Volume: 85, Issue:4

    Topics: Adult; Aminophylline; Asthma; Female; Humans; Hypoxanthine; Hypoxanthines; Male; Middle Aged; Pulmon

1991
Trends and district variations in the hospital care of childhood asthma: results of a regional study 1970-85.
    Thorax, 1990, Volume: 45, Issue:6

    Topics: Acute Disease; Administration, Inhalation; Administration, Oral; Adolescent; Adrenal Cortex Hormones

1990